MedTrace Logo

Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging

NCT05700006 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 94

Last updated 2026-03-05

No results posted yet for this study

Summary

The goal of this pilot observational study is to learn about the feasibility of collecting patient-reported data and stool and blood samples from patients age 65 and older treated with aromatase inhibitor therapy for breast cancer. Participants will be treated with standard of care aromatase inhibitor therapy and will undergo serial phlebotomy, complete patient-reported questionnaires, and submit serial stool samples.

The main exploratory translational questions it aims to obtain preliminary data for are:

* What are the effects of aromatase inhibitor therapy on biomarkers of aging?
* What are the effects of aromatase inhibitor therapy on the microbiome? These data will be used for the development of future definitive studies.

Conditions

Interventions

DRUG

Aromatase inhibitor

Standard of care anastrozole, exemestane, or letrozole

Sponsors & Collaborators

Principal Investigators

  • Norah L Henry, MD, PhD · University of Michigan

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-25
Primary Completion
2026-02-26
Completion
2026-02-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05700006 on ClinicalTrials.gov